Yahoo
Shanghai - Delayed Quote CNY

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SS)

20.08 +0.11 (+0.55%)
At close: 3:00:01 PM GMT+8
Chart Range Bar
Loading chart for 600332.SS
  • Previous Close 19.97
  • Open 20.00
  • Bid 20.07 x --
  • Ask 20.08 x --
  • Day's Range 19.96 - 20.15
  • 52 Week Range 19.30 - 27.50
  • Volume 6,832,774
  • Avg. Volume 9,328,117
  • Market Cap (intraday) 32.646B
  • Beta (5Y Monthly) 0.18
  • PE Ratio (TTM) 12.71
  • EPS (TTM) 1.58
  • Earnings Date (est.) --
  • Forward Dividend & Yield 0.75 (3.80%)
  • Ex-Dividend Date Sep 10, 2026
  • 1y Target Est 22.66

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, development, manufacturing, and sale of chemical drugs, chemical raw materials, and chemical raw material intermediates; and research, development, production, and sale of health products; and wholesale, retail, and import export of Western medicines, traditional Chinese medicines, and medical devices. The company also offers bio-innovation, consumer health, and medical services; Xiaochaihu granules; Qingkailing and Baoji, Xia Sangju product series; Angong Niuhuang, Zishen Yutai, Xiaoke, Huatuo Zaizao, Zhuangyao Jianshen, and Shujin Jianyao pills; compound Danshen and Naoxinqing tablet series; Banlangen, Compound Banlangen, and Dashen Kouyanqing granules series; and honey-processed Chuanbei and Shedan Chuanbei loquat syrup. In addition, it provides antibacterial and anti-inflammatory drugs, andrological drugs, and analgesics and antipyretics; Wanglaoji herbal tea, Ciningji series, Lixiaoji series, and Yerou coconut milk; and advertising services. Further, the company engages in the medical research industry; technology services industry; leasing and business services; and scientific research and technical services industry. It operates through hospitals, community healthcare facilities, and retail outlets through distributors and agents. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.

www.gybys.com.cn

26,365

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 10/12/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600332.SS
19.14%
SSE Composite Index (000001.SS)
4.32%

1-Year Return

600332.SS
19.27%
SSE Composite Index (000001.SS)
2.56%

3-Year Return

600332.SS
28.35%
SSE Composite Index (000001.SS)
22.18%

5-Year Return

600332.SS
22.52%
SSE Composite Index (000001.SS)
7.06%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY24
Revenue 18.02B
Earnings --
Profit Margin 0.00%

Q4

FY23

Q1

FY24

Q2

FY24

Q3

FY24

0
5B
10B
15B
20B
0.0%

Analyst Insights

View More

Analyst Price Targets

15.40 Low
22.66 Average
20.08 Current
29.92 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    30.15B

  • Enterprise Value

    36.41B

  • Trailing P/E

    12.48

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.41

  • Price/Book (mrq)

    0.82

  • Enterprise Value/Revenue

    0.47

  • Enterprise Value/EBITDA

    8.05

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.29%

  • Return on Assets (ttm)

    2.09%

  • Return on Equity (ttm)

    6.50%

  • Revenue (ttm)

    77.91B

  • Net Income Avi to Common (ttm)

    2.56B

  • Diluted EPS (ttm)

    1.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    25.66B

  • Total Debt/Equity (mrq)

    47.83%

  • Levered Free Cash Flow (ttm)

    -479.6M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: